What the U.S. POINTER results mean for public health initiatives and the Alzheimer's Association

Abstract

The Alzheimer's Association launched the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER), a 2 year clinical trial to evaluate whether lifestyle or behavioral interventions that simultaneously target multiple risk factors protect cognitive function in > 2000 older adults (ages 60–79) at increased risk for cognitive decline. Top‐line results from the study demonstrated that a structured, multi‐domain lifestyle intervention significantly reduces cognitive decline compared to a self‐guided approach over the 2 year interventions. U.S. POINTER positive trial results have far‐reaching implications for public health, clinical care, and possibly dementia prevention strategies in the United States and the world. This perspective describes the implications and the Alzheimer's Association's commitment to creating the conditions that make this possible; activating individuals, communities, and organizations to take charge of and improve their brain health and creating conditions or environments for the success of implementation in communities.

Highlights

• A growing body of evidence suggests that lifestyle modifications may play a critical role in reducing the risk of cognitive decline and dementia.

• U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) positive trial results have far‐reaching implications for public health, clinical care, and possibly dementia prevention strategies in the United States and the world.

• U.S. POINTER will significantly inform public health action on a multi‐domain intervention for an at‐risk population.

• Continued analysis of trial data, including biomarkers, along with insights from the Alzheimer's Association‐funded Alumni Extension study, will offer additional insights on the impact of the trial intervention and provide valuable guidance on how best to adapt the intervention for diverse communities.

1. INTRODUCTION

A growing body of evidence suggests that lifestyle modifications may play a critical role in reducing the risk of cognitive decline and dementia. Unlike pharmacological treatments, lifestyle or behavioral interventions can simultaneously address multiple potential contributing causes or risk factors as an intervention strategy to impact the downstream risk of cognitive decline or dementia. ¹ Past work has suggested that up to 45% of dementia cases globally are attributable to modifiable lifestyle and vascular/metabolic risk factors, including diabetes, midlife hypertension, midlife obesity, physical inactivity, depression, smoking, and low educational attainment. ² Modeling studies suggest that reducing the prevalence of each of these risk factors by just 10% to 20% per decade could lead to an 8% to 15% decline in global AD prevalence by 2050. ³ Interventions with sustained improvements in risk factors that could reduce risk of cognitive decline and dementia have substantial public health impact, particularly over time. Data from other work suggest that such interventions may also impact a population's overall health, leading to lower disability and cardiovascular disease, as well as greater mobility in the population.

Cognitive decline and dementia, including Alzheimer's disease (AD) and related dementias (ADRD), are a significant and growing public health challenge in the United States, as well as around the world. According to the Alzheimer's Association's 2025 Facts & Figures report, an estimated 7.2 million older Americans are living with AD dementia—the most common form of dementia—and this number is projected to double by 2060. ⁴ Another 5 to 7 million older Americans may have mild cognitive impairment (MCI) due to AD. ⁴ This estimate is based on individuals living with clinically diagnosed AD dementia, but not confirmed by specific biomarkers of AD. The prevalence data that link clinical diagnosis with biological confirmation are emerging. Data from other work, such as the Imaging Dementia–Evidence for Amyloid Scanning study, tell us that clinical diagnosis of AD dementia is 70% accurate, with 30% having another cause of the clinical symptoms, while in individuals with MCI, all cause, 55% is due to AD and 45% is due to other causes. ⁵ Individuals at risk for cognitive decline and dementia are inclusive of all causes of dementia, and in many cases, may include other conditions that could contribute to a person's risk of cognitive decline, including cardiovascular disease and diabetes mellitus type 2. In the context of the larger scientific landscape, the population impact of these health issues underscores the urgent need for the development of effective and scalable risk reduction and prevention strategies to mitigate the growing societal, economic, and health‐care burden of cognitive decline, especially as it contributes to and potentially accelerates in AD/ADRD.

2. THE US POINTER STUDY: DESIGN, OVERVIEW, AND KEY FINDINGS

Developing sustainable, real‐world interventions that benefit all communities has remained a challenge. To bridge this gap, the Alzheimer's Association launched the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). U.S. POINTER is a 2 year clinical trial to evaluate whether lifestyle or behavioral interventions that simultaneously target multiple risk factors protect cognitive function in older adults (ages 60–79) at increased risk for cognitive decline. It is the first such study to be conducted in a large group of US residents. ⁶ The detailed methods of the trial are published. ⁶ The study enrolled > 2100 US adults who were randomized to self‐guided or structured interventions. ⁷ Over the 2 years of the intervention, participants’ adherence to the intervention, as well as clinical and cognitive assessments every 6 months, were tracked by the study team.

Top‐line results from the study were presented at the Alzheimer's Association International Conference (AAIC) 2025. ⁸ , ⁹ Results demonstrated that a structured, multi‐domain lifestyle intervention significantly reduces cognitive decline compared to a self‐guided approach over the 2 year intervention. These findings not only validate decades of observational research linking lifestyle factors to cognitive health but also align with results from international trials, ¹⁰ such as the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). ¹¹ U.S. POINTER saw a similar impact on cognitive domains to the FINGER study. Importantly, U.S. POINTER's positive results demonstrate the generalizability and adaptability of the multi‐domain intervention model in a culturally and geographically representative American population. It confirms that a multi‐domain intervention, when delivered within the structured intervention framework of support by a navigator, specific recommendations, regular team meetings, and weekly goals, can effectively protect brain health in older adults at elevated risk for dementia.

After the announcement of top‐line results at AAIC 2025, continued analysis of trial data, including biomarkers, along with insights from the Alzheimer's Association–funded Alumni Extension study, will offer additional insights on the impact of the trial intervention and provide valuable guidance on how best to adapt the intervention for diverse communities.

3. PUBLIC HEALTH IMPLICATIONS AND THE ROLE OF THE ALZHEIMER'S ASSOCIATION

The positive outcomes of U.S. POINTER have far‐reaching implications for public health, clinical care, and possibly dementia prevention strategies in the United States. The trial results show that individuals and communities—either through system approaches, public health, or individual approaches—can be empowered to take proactive steps toward protecting their brain health. The Alzheimer's Association is committed to creating the conditions that make this possible by activating individuals, communities, and organizations to take charge of and improve their brain health and create the conditions or environment for success. This means raising awareness, fostering local engagement, and making brain health a visible and actionable opportunity in everyday life in the community.

This approach begins with implementation science. While the trial provides a compelling blueprint for action, the next challenge lies in translating this evidence into practice. Achieving this requires investment in implementation science, strategic partnerships, and systems‐level changes to allow embedding brain health promotion across systems of care.

While randomized controlled trials, such as U.S. POINTER, provide the roadmap for what works, implementation science tells us how to make it work in real‐world settings. To turn brain health interventions into lasting public health solutions, it is essential to bridge the gap between clinical evidence and community adoption. Implementation research, including pilot studies, is essential to understand how best to adapt and scale interventions in diverse clinical and community settings. To that end, the Alzheimer's Association is committing $40 million over the next 4 years, including the continued follow‐up of U.S. POINTER study participants and beginning with a series of planning grants, to develop and test specific strategies for real‐world implementation that can be sustained and scaled across community and health‐care settings.

While U.S. POINTER provides an evidence‐based framework that can inform the future of brain health promotion and intervention programming in the United States, it does not define the full scope of the Alzheimer's Association's commitment to dementia prevention. The Alzheimer's Association's brain health strategy is not limited to the specific components of the U.S. POINTER intervention—or of implementation science on the intervention. Rather, it encompasses a broader, long‐term vision for reducing dementia risk at the population level, promoting brain health across the lifespan, and ensuring that everyone can lead a life with the healthiest brain possible.

Through its ongoing efforts—such as the Center of Excellence on Dementia Risk Reduction and the Healthy Brain Initiative (both funded by the Centers for Disease Control and Prevention) as well as 10 Healthy Habits, partnerships with health‐care systems, education programs, and engagement with public health officials across the country—the Alzheimer's Association has demonstrated a strong commitment to integrating brain health into public health practice. ¹² These efforts—grounded primarily in decades of observational research and international trials—will continue.

Now, in the context of the positive U.S. POINTER results, the Alzheimer's Association is poised to expand and accelerate the promotion of brain health throughout the population. The Alzheimer's Association will be helping individuals prioritize brain health through the creation of their own brain health “game plan.” Primary care providers will have access to an interactive case‐based virtual brain health training program. Communities will be equipped to support brain‐healthy lifestyles through a new Community Recognition Program that recognizes employers, health‐care systems, and communities that champion brain health and, because few public health efforts succeed without broad‐based partnerships, the Alzheimer's Association is establishing a Brain Health Roundtable to bring together the brightest minds among health care, public health, community organizations, and corporate leaders to build momentum for a brain‐healthy America.

4. CONCLUSION

The Alzheimer's Association recognizes the importance of providing clear, scientific communication to the larger community audience, making them aware of the outcomes of this study. Toward that end, the Alzheimer's Association will continue to serve as a trusted source of knowledge by fostering understanding of what the U.S. POINTER results mean and what individuals, communities, providers, and health systems can do. While the U.S. POINTER findings offer strong evidence that a structured, multi‐domain program can reduce cognitive decline in an at‐risk population, the trial was not designed to assess dementia incidence or the independent effect of any single intervention component in the initial timeline. But, combined with decades of population‐level, observational research, U.S. POINTER underscores the promise of robust, scientifically grounded brain health–promotion strategies.

U.S. POINTER will significantly inform public health action on a multi‐domain intervention for an at‐risk population. While it is unclear the impact on a population without the presence of a risk profile, the larger literature would suggest that the population at large will also benefit from a similar strategy of risk reduction. Additional analysis from U.S. POINTER in the coming months and years will further evaluate AD and vascular contributions to cognitive impairment and dementia (VCID)–specific contributions and the biological impact of the interventions. This may inform even more detailed recommendations for those with comorbid conditions, such as cardiovascular disease or metabolic disorders. The Alumni Extension for U.S. POINTER will be essential in further defining the long‐term impact of the interventions, and robust implementation science will be essential to bringing the proven intervention to communities.

CONFLICT OF INTEREST STATEMENT

M.C.C., H.M.S., M.B., K.J.P. are all full‐time employees of the Alzheimer's Association. M.C.C. has a child who is a graduate student at the University of Southern California. H.M.S.’s spouse is an employee at Abbott Labs in an unrelated field. Author disclosures are available in the supporting information.

Supporting information

Supporting Information

Carrillo MC, Snyder H, Baumgart M, Pike KJ. What the U.S. POINTER results mean for public health initiatives and the Alzheimer's Association. Alzheimer's Dement. 2025;21:e70556. 10.1002/alz.70556